Myoblast transplantation: The current status of a potential therapeutic tool for myopathies

Journal of Muscle Research and Cell Motility

Volumn 24, Issue 4-6, 2003, Pages 285-300

  Skuk, Daniel ^a   Tremblay, Jacques P ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ANIMAL CELL; AUTOTRANSPLANTATION; BONE MARROW CELL; CELL SURVIVAL; CELL TRANSPLANTATION; CONFERENCE PAPER; DUCHENNE MUSCULAR DYSTROPHY; FIBROBLAST; GENETIC COMPLEMENTATION; GRAFT REJECTION; HEMATOPOIETIC CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MONKEY; MOUSE; MYOBLAST; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; SATELLITE CELL; SELF INCOMPATIBILITY; STEM CELL TRANSPLANTATION; STROMA CELL;

ANIMALS; CELL SURVIVAL; CELL TRANSPLANTATION; HUMANS; MUSCULAR DISEASES; MYOBLASTS;

ANIMALIA; PRIMATES;

EID: 0142249453     PISSN: 01424319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (175)

1. Abassi ZA, Hoffman A and Better OS (1998) Acute renal failure complicating muscle crush injury. Semin Nephrol 18: 558-565.
2. Alameddine HS, Louboutin JP, Dehaupas M, Sebille A and Fardeau M (1994) Functional recovery induced by satellite cell grafts in irreversibly injured muscles. Cell Transplant 3: 3-14.
3. Appleyard ST, Dunn MJ, Dubowitz V and Rose ML (1985) Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders. Lancet 1: 361-363.
4. Arcila ME, Ameredes BT, DeRosimo JF, Washabaugh CH, Yang J, Johnson PC and Ontell M (1997) Mass and functional capacity of regenerating muscle is enhanced by myoblast transfer. J Neurobiol 33: 185-198.
5. Asakura A, Seale P, Girgis-Gabardo A and Rudnicki MA (2002) Myogenic specification of side population cells in skeletal muscle. J Cell Biol 159: 123-134.
6. Asselin I, Tremblay M, Vilquin JT, Guerette B, Roy R and Tremblay JP (1995) Quantification of normal dystrophin mRNA following myoblast transplantation in mdx mice. Muscle Nerve 18: 980-986.
7. Bao S, dos Remedios CG and King NJ (1994) Ontogeny of major histocompatibility complex antigen expression on cultured human embryonic skeletal myoblasts. Transplantation 58: 585-591.
8. Beauchamp JR, Morgan JE, Pagel CN and Partridge TA (1999) Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J Cell Biol 144: 1113-1122.
9. Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H and Hohlfeld R (1998) Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 161: 5943-5951.
10. Belles-Isles M, Roy R, Dansereau G, Goulet M, Roy B, Bouchard JP and Tremblay JP (1993) Rapid selection of donor myoblast clones for muscular dystrophy therapy using cell surface expression of NCAM. Eur J Histochem 37: 375-380.
11. Birmingham K (1997) Controversial muscular dystrophy therapy goes to court. Nat Med 3: 1058.
12. Bischoff R (1975) Regeneration of single skeletal muscle fibers in vitro. Anat Rec 182: 215-235.
13. Bonavaud S, Agbulut O, Nizard R, D'Honneur G, Mouly V and Butler-Browne G (2001) A discrepancy resolved: human satellite cells are not preprogrammed to fast and slow lineages. Neuromuscul Disord 11: 747-752.
14. Bonilla E, Schmidt B, Samitt CE, Miranda AF, Hays AP, de Oliveira AB, Chang HW, Servidei S, Ricci E, Younger DS et al. (1988) Normal and dystrophin-deficient muscle fibers in carriers of the gene for Duchenne muscular dystrophy. Am J Pathol 133: 440-445.
15. Borisov AB (1999) Regeneration of skeletal and cardiac muscle in mammals: do nonprimate models resemble human pathology? Wound Repair Regen 7: 26-35.
16. Boulanger A, Asselin I, Roy R and Tremblay JP (1997) Role of non-major histocompatibility complex antigens in the rejection of transplanted myoblasts. Transplantation 63: 893-899.
17. Brazelton TR and Morris RE (1996) Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 8: 710-720.
18. Brussee V, Merly F, Tardif F and Tremblay JP (1998) Normal myoblast implantation in MDX mice prevents muscle damage by exercise. Biochem Biophys Res Commun 250: 321-327.
19. Bujold M, Caron N, Camiran G, Mukherjee S, Allen PD, Tremblay JP and Wang Y (2002) Autotransplantation in mdx mice of mdx myoblasts genetically corrected by an HSV-1 amplicon vector. Cell Transplant 11: 759-767.
20. Camirand G, Caron NJ, Asselin I and Tremblay JP (2001) Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. Transplantation 72: 38-44.
21. Camirand G, Caron NJ, Turgeon NA, Rossini AA and Tremblay JP (2002) Treatment with anti-CD154 antibody and donor-specific transfusion prevents acute rejection of myoblast transplantation. Transplantation 73: 453-461.
22. Cantini M, Massimino ML, Catani C, Rizzuto R, Brini M and Carraro U (1994) Gene transfer into satellite cell from regenerating muscle: bupivacaine allows beta-Ga1 transfection and expression in vitro and in vivo. In Vitro Cell Dev Biol Anim 30A: 131-133.
23. Cardasis CA and Cooper GW (1975) An analysis of nuclear numbers in individual muscle fibers during differentiation and growth: a satellite cell-muscle fiber growth unit. J Exp Zool 191: 347-358.
24. Caron NJ, Asselin I, Morel G and Tremblay JP (1999) Increased myogenic potential and fusion of matrilysin-expressing myoblasts transplanted in mice. Cell Transplant 8: 465-476.
25. Cifuentes-Diaz C, Delaporte C, Dautreaux B, Charron D and Fardeau M (1992) Class II MHC antigens in normal human skeletal muscle. Muscle Nerve 15: 295-302.
26. Corti S, Strazzer S, Del Bo R, Salani S, Bossolasco P, Fortunato F, Locatelli F, Soligo D, Moggio M, Ciscato P, Prelle A, Borsotti C, Bresolin N, Scarlato G and Comi GP (2002) A subpopulation of murine bone marrow cells fully differentiates along the myogenic pathway and participates in muscle repair in the mdx dystrophic mouse. Exp Cell Res 277: 74-85.
27. Curnow SJ, Willcox N and Vincent A (1998) Induction of primary immune responses by allogeneic human myoblasts: dissection of the cell types required for proliferation, IFNgamma secretion and cytotoxicity. J Neuroimmunol 86: 53-62.
28. Deasy BM, Jankowski RJ and Huard J (2001) Muscle-derived stem cells: characterization and potential for cell-mediated therapy. Blood Cells Mol Dis 27: 924-933.
29. Di Blasi C, Morandi L, Barresi R, Blasevich F, Cornelio F and Mora M (1996) Dystrophin-associated protein abnormalities in dystrophin-deficient muscle fibers from symptomatic and asymptomatic Duchenne/Becker muscular dystrophy carriers. Acta Neuropathol (Berl) 92: 369-377.
30. El Fahime E, Mills P, Lafreniere JF, Torrente Y and Tremblay JP (2002) The urokinase plasminogen activator: an interesting way to improve myoblast migration following their transplantation. Exp Cell Res 280: 169-178.
31. El Fahime E, Torrente Y, Caron NJ, Bresolin MD and Tremblay JP (2000) In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity. Exp Cell Res 258: 279-287.
32. Emslie-Smith AM, Arahata K and Engel AG (1989) Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 20: 224-231.
33. Ennis BW and Matrisian LM (1994) Matrix degrading metalloproteinases. J Neurooncol 18: 105-109.
34. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G and Mavilio F (1998) Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279: 1528-1530.
35. Ferrari G, Stornaiuolo A and Mavilio F (2001) Failure to correct murine muscular dystrophy. Nature 411: 1014-1015.
36. Floyd SS Jr, Clemens PR, Ontell MR, Kochanek S, Day CS, Yang J, Hauschka SD, Balkir L, Morgan J, Moreland MS, Feero GW, Epperly M and Huard J (1998) Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther 5: 19-30.
37. Garlepp MJ, Chen W, Tabarias H, Baines M, Brooks A and McCluskey J (1995) Antigen processing and presentation by a murine myoblast cell line. Clin Exp Immunol 102: 614-619.
38. Gasque P, Morgan BP, Legoedec J, Chan P and Fontaine M (1996) Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing. J Immunol 156: 3402-3411.
39. Geluk A, Elferink DG, Slierendregt BL, van Meijgaarden KE, de Vries RR, Ottenhoff TH and Bontrop RE (1993) Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates. J Exp Med 177: 979-987.
40. Ghins E, Colson-Van Schoor M and Marechal G (1986) Implantation of autologous cells in minced and devitalized rat skeletal muscles. J Muscle Res Cell Motil 7: 151-159.
41. Gill RG and Wolf L (1995) Immunobiology of cellular transplantation. Cell Transplant 4: 361-370.
42. Goebels N, Michaelis D, Wekerle H and Hohlfeld R (1992) Human myoblasts as antigen-presenting cells. J Immunol 149: 661-667.
43. Goldring K, Jones GE, Thiagarajah R and Watt DJ (2002) The effect of galectin-1 on the differentiation of fibroblasts and myoblasts in vitro. J Cell Sci 115: 355-366.
44. Grigoriadis AE, Heersche JN and Aubin JE (1988) Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. J Cell Biol 106: 2139-2151.
45. Gross JG and Morgan JE (1999) Muscle precursor cells injected into irradiated mdx mouse muscle persist after serial injury. Muscle Nerve 22: 174-185.
46. Grounds MD (1983) Skeletal muscle precursors do not arise from bone marrow cells. Cell Tissue Res 234: 713-722.
47. Guerette B, Asselin I, Skuk D, Entman M and Tremblay JP (1997a) Control of inflammatory damage by anti-LFA-1: increase success of myoblast transplantation. Cell Transplant 6: 101-107.
48. Guerette B, Asselin I, Vilquin JT, Roy R and Tremblay JP (1995a) Lymphocyte infiltration following allo-and xenomyoblast transplantation in mdx mice. Muscle Nerve 18: 39-51.
49. Guerette B, Gingras M, Wood K, Roy R and Tremblay JP (1996a) Immunosuppression with monoclonal antibodies and CTLA4-Ig after myoblast transplantation in mice. Transplantation 62: 962-967.
50. Guerette B, Roy R, Tremblay M, Asselin I, Kinoshita I, Puymirat J and Tremblay JP (1995b) Increased granzyme B mRNA after alloincompatible myoblast transplantation. Transplantation 60: 1011-1016.
51. Guerette B, Skuk D, Celestin F, Huard C, Tardif F, Asselin I, Roy B, Goulet M, Roy R, Entman M and Tremblay JP (1997b) Prevention by anti-LFA-1 of acute myoblast death following transplantation. J Immunol 159: 2522-2531.
52. Guerette B, Tremblay G, Vilquin JT, Asselin I, Gingras M, Roy R and Tremblay JP (1996b) Increased interferon-gamma mRNA expression following alloincompatible myoblast transplantation is inhibited by FK506. Muscle Nerve 19: 829-835.
53. Gummert JF, Ikonen T and Morris RE (1999) Newer immunosuppressive drugs: a review. J Am Soc Nephrol 10: 1366-1380.
54. Gussoni E, Bennett RR, Muskiewicz KR, Meyerrose T, Nolta JA, Gilgoff I, Stein J, Chan YM, Lidov HG, Bonnemann CG, Von Moers A, Morris GE, Den Dunnen JT, Chamberlain JS, Kunkel LM and Weinberg K (2002) Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest 110: 807-814.
55. Gussoni E, Blau HM and Kunkel LM (1997) The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 3: 970-977.
56. Gussoni E, Pavlath GK, Lanctot AM, Sharma KR, Miller RG, Steinman L and Blau HM (1992) Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 356: 435-438.
57. Gussoni E, Soneoka Y, Strickland CD, Buzney EA, Khan MK, Flint AF, Kunkel LM and Mulligan RC (1999) Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401: 390-394.
58. Hall ZW and Ralston E (1989) Nuclear domains in muscle cells. Cell 59: 771-772.
59. Hardiman O, Faustman D, Li X, Sklar RM and Brown RH Jr (1993a) Expression of major histocompatibility complex antigens in cultures of clonally derived human myoblasts. Neurology 43: 604-608.
60. Hardiman O, Sklar RM and Brown RH Jr (1993b) Direct effects of cyclosporin A and cyclophosphamide on differentiation of normal human myoblasts in culture. Neurology 43: 1432-1434.
61. Harris JB and Cullen MJ (1990) Muscle necrosis caused by snake venoms and toxins. Electron Microsc Rev 3: 183-211.
62. Heslop L, Beauchamp JR, Tajbakhsh S, Buckingham ME, Partridge TA and Zammit PS (2001) Transplanted primary neonatal myoblasts can give rise to functional satellite cells as identified using the Myf5(nlacZl+) mouse. Gene Ther 8: 778-783.
63. Hodgetts SI and Grounds MD (2001) Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5. Immunol Cell Biol 79: 231-239.
64. Hodgetts SI, Beilharz MW, Scalzo AA and Grounds MD (2000) Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplant 9: 489-502.
65. Hohlfeld R and Engel AG (1990) Induction of HLA-DR expression on human myoblasts with interferon-gamma. Am J Pathol 136: 503-508.
66. Hong F, Lee J, Song JW, Lee SJ, Ahn H, Cho JJ, Ha J and Kim SS (2002) Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity. Faseb J 16: 1633-1635.
67. Huard J, Bouchard JP, Roy R, Labrecque C, Dansereau G, Lemieux B and Tremblay JP (1991) Myoblast transplantation produced dystrophin-positive muscle fibres in a 16-year-old patient with Duchenne muscular dystrophy. Clin Sci (Colch) 81: 287-288.
68. Huard J, Bouchard JP, Roy R, Malouin F, Dansereau G, Labrecque C, Albert N, Richards CL, Lemieux B and Tremblay JP (1992) Human myoblast transplantation: preliminary results of 4 cases. Muscle Nerve 15: 550-560.
69. Huard C, Moisset PA, Dicaire A, Merly F, Tardif F, Asselin I and Tremblay JP (1998) Transplantation of dermal fibroblasts expressing MyoD1 in mouse muscles. Biochem Biophys Res Commun 248: 648-654.
70. Huard J, Verreault S, Roy R, Tremblay M and Tremblay JP (1994) High efficiency of muscle regeneration after human myoblast clone transplantation in SCID mice. J Clin Invest 93: 586-599.
71. Hughes SM and Blau HM (1990) Migration of myoblasts across basal lamina during skeletal muscle development. Nature 345: 350-353.
72. Irintchev A, Langer M, Zweyer M, Theisen R and Wernig A (1997) Functional improvement of damaged adult mouse muscle by implantation of primary myoblasts. J Physiol (Lond) 500: 775-785.
73. Irintchev A, Rosenblatt JD, Cullen MJ, Zweyer M and Wernig A (1998) Ectopic skeletal muscles derived from myoblasts implanted under the skin. J Cell Sci 111: 3287-3297.
74. Irintchev A, Zweyer M and Wernig A (1995) Cellular and molecular reactions in mouse muscles after myoblast implantation. J Neurocytol 24: 319-331.
75. Ito H, Hallauer PL, Hastings KE and Tremblay JP (1998a) Prior culture with concanavalin A increases intramuscular migration of transplanted myoblast. Muscle Nerve 21: 291-297.
76. Ito H, Vilquin JT, Skuk D, Roy B, Goulet M, Lille S, Dugre FJ, Asselin I, Roy R, Fardeau M and Tremblay JP (1998b) Myoblast transplantation in non-dystrophic dog. Neuromuscul Disord 8: 95-110.
77. Iwamoto Y and Sugioka Y (1992) Use of a reconstituted basement membrane to study the invasiveness of tumor cells. Adv Exp Med biol 324: 141-149.
78. Jaeger EE, Bontrop RE and Lanchbury JS (1994) Structure, diversity, and evolution of the T-cell receptor VB gene repertoire in primates. Immunogenetics 40: 184-191.
79. Karpati G, Ajdukovic D, Arnold D, Gledhill RB, Guttman R, Holland P, Koch PA, Shoubridge E, Spence D, Vanasse M, Watters GV, Abrahamowicz M, Duff C and Worton RG (1993) Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 34: 8-17.
80. Karpati G, Johnston W, Ajdukovic G, Arnold D, Vanasse M, Guttmann R, Crerar M, Carpenter S and Shoubridge E (1992) Myoblast transfer (MT) in McArdle's disease (McD). Neurology 42(Suppl 3): 387.
81. Karpati G, Pouliot Y and Carpenter S (1988) Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 23: 64-72.
82. Kinoshita I, Roy R, Dugre FJ, Gravel C, Roy B, Goulet M, Asselin I and Tremblay JP (1996a) Myoblast transplantation in monkeys: control of immune response by FK506. J Neuropathol Exp Neurol 55: 687-697.
83. Kinoshita I, Vilquin JT, Asselin I, Chamberlain J and Tremblay JP (1998) Transplantation of myoblasts from a transgenic mouse overexpressing dystrophin produced only a relatively small increase of dystrophin-positive membrane. Muscle Nerve 21: 91-103.
84. Kinoshita I, Vilquin JT, Gravel C, Roy R and Tremblay JP (1995a) Myoblast allotransplantation in primates. Muscle Nerve 18: 1217-1218.
85. Kinoshita I, Vilquin JT, Guerette B, Asselin I, Roy R and Tremblay JP (1994) Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 17: 1407-1415.
86. Kinoshita I, Vilquin JT and Tremblay JP (1995b) Pretreatment of myoblast cultures with basic fibroblast growth factor increases the efficacy of their transplantation in mdx mice. Muscle Nerve 18: 834-841.
87. Kinoshita I, Vilquin JT and Tremblay JP (1996b) Mechanism of increasing dystrophin-positive myofibers by myoblast transplantation: study using mdx/beta-galactosidase transgenic mice. Acta Neuropathol 91: 489-493.
88. Knechtle SJ (2000) Knowledge about transplantation tolerance gained in primates. Curr Opin Immunol 12: 552-556.
89. Law PK, Goodwin TG and Wang MG (1988) Normal myoblast injections provide genetic treatment for murine dystrophy. Muscle Nerve 11: 525-533.
90. Leriche-Guerin K, Anderson LV, Wrogemann K, Roy B, Goulet M and Tremblay JP (2002) Dysferlin expression after normal myoblast transplantation in SCID and in SJL mice. Neuromuscul Disord 12: 167-173.
91. Levinson G, Hughes AL and Letvin NL (1992) Sequence and diversity of rhesus monkey T-cell receptor beta chain genes. Immunogenetics 35: 75-88.
92. Li YY and Cheung HT (1992) Basement membrane and its components on lymphocyte adhesion, migration, and proliferation. J Immunol 149: 3174-3181.
93. Mantegazza R, Hughes SM, Mitchell D, Travis M, Blau HM and Steinman L (1991) Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma. Neurology 41: 1128-1132.
94. McDouall RM, Dunn MJ and Dubowitz V (1989) Expression of class I and class II MHC antigens in neuromuscular diseases. J Neurol Sci 89: 213-226.
95. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, Sahenk Z, Benson S, McAndrew PE, Rice R, Nagaraja H, Stephens R, Lantry L, Morris GE and Burghes AHM (1995) Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 333: 832-838.
96. Merly F, Huard C, Asselin I, Robbins PD and Tremblay JP (1998) Anti-inflammatory effect of transforming growth factor-beta1 in myoblast transplantation. Transplantation 65: 793-799.
97. Meyer S and Yarom R (1983) Muscle regeneration and transplantation enhanced by bone marrow cells. Br J Exp Pathol 64: 15-24.
98. Michaelis D, Goebels N and Hohlfeld R (1993) Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 143: 1142-1149.
99. Miller RG, Sharma KR, Pavlath GF, Gussoni E, Mynhier M, Lanctot AM, Greco CM, Steinman L and Blau HM (1997) Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle Nerve 20: 469-478.
100. Moisset PA, Gagnon Y, Karpati G and Tremblay JP (1998a) Expression of human dystrophin following the transplantation of genetically modified mdx myoblasts. Gene Ther 5: 1340-1346.
101. Moisset PA, Skuk D, Asselin I, Goulet M, Roy B, Karpati G and Tremblay JP (1998b) Successful transplantation of genetically corrected DMD myoblasts following ex vivo transduction with the dystrophin minigene. Biochem Biophys Res Commun 247: 94-99.
102. Morgan JE, Coulton GR and Partridge TA (1987) Muscle precursor cells invade and repopulate freeze-killed muscles. J Muscle Res Cell Motil 8: 386-396.
103. Morgan JE, Hoffman EP and Partridge TA (1990) Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. J Cell Biol 111: 2437-2449.
104. Morgan JE, Pagel CN, Sherratt T and Partridge TA (1993) Long-term persistence and migration of myogenic cells injected into pre-irradiated muscles of mdx mice. J Neurol Sci 115: 191-200.
105. Munoz-Canoves P, Miralles F, Baiget M and Felez J (1997) Inhibition of urokinase-type plasminogen activator (uPA) abrogates myogenesis in vitro. Thromb Haemost 77: 526-534.
106. Neumeyer AM, Cros D, McKenna-Yasek D, Zawadzka A, Hoffman EP, Pegoraro E, Hunter RG, Munsat TL and Brown RH Jr (1998) Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy. Neurology 51: 589-592.
107. Neumeyer AM, DiGregorio DM and Brown RH Jr (1992) Arterial delivery of myoblasts to skeletal muscle. Neurology 42: 2258-2262.
108. Ohtsuka Y, Udaka K, Yamashiro Y, Yagita H and Okumura K (1998) Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: implication for gene therapy. J Immunol 160: 4635-4640.
109. Partridge TA (1991) Invited review: myoblast transfer: a possible therapy for inherited myopathies? Muscle Nerve 14: 197-212.
110. Partridge T, Beauchamp J, Morgan J, Tremblay JP, Huard J, Watt D, Wernig A, Irintchev A, Grounds M, Springer ML, Bartlett RJ, Mendell J, Vilquin JT and Bower JJ (1997) Meeting of the Cell Transplantation Society in Miami. Cell Transplant 6: 195-198.
111. Partridge TA, Grounds M and Sloper JC (1978) Evidence of fusion between host and donor myoblasts in skeletal muscle grafts. Nature 273: 306-308.
112. Partridge T, Lu QL, Morris G and Hoffman E (1998) Is myoblast transplantation effective? Nat Med 4: 1208-1209.
113. Partridge TA, Morgan JE, Coulton GR, Hoffman EP and Kunkel LM (1989) Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337: 176-179.
114. Pavlath GK, Rando TA and Blau HM (1994) Transient immunosuppressive treatment leads to long-term retention of allogeneic myoblasts in hybrid myofibers. J Cell Biol 127: 1923-1932.
115. Pavlath GK, Rich K, Webster SG and Blau HM (1989) Localization of muscle gene products in nuclear domains. Nature 337: 570-573.
116. Pin CL and Merrifield PA (1997) Developmental potential of rat L6 myoblasts in vivo following injection into regenerating muscles. Dev Biol 188: 147-166.
117. Polinger IS (1970) Separation of cell types in embryonic heart cell cultures. Exp Cell Res 63: 78-82.
118. Ponder BA, Wilkinson MM, Wood M and Westwood JH (1983) Immunohistochemical demonstration of H2 antigens in mouse tissue sections. J Histochem Cytochem 31: 911-919.
119. Qu Z and Huard J (2000) Matching host muscle and donor myoblasts for myosin heavy chain improves myoblast transfer therapy. Gene Ther 7: 428-437.
120. Qu Z, Balkir L, van Deutekom JC, Robbins PD, Pruchnic R and Huard J (1998) Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol 142: 1257-1267.
121. Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, Pruchnic R, Mytinger J, Cao B, Gates C, Wernig A and Huard J (2002) Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol 157: 851-864.
122. Ralston E and Hall ZW (1992) Restricted distribution of mRNA produced from a single nucleus in hybrid myotubes. J Cell Biol 119: 1063-1068.
123. Rando TA, Pavlath GK and Blau HM (1995) The fate of myoblasts following transplantation into mature muscle. Exp Cell Res 220: 383-389.
124. Robertson TA, Grounds MD and Papadimitriou JM (1992) Elucidation of aspects of murine skeletal muscle regeneration using local and whole body irradiation. J Anat 181(Pt 2): 265-276.
125. Rosenblatt JD and Parry DJ (1992) Gamma irradiation prevents compensatory hypertrophy of overloaded mouse extensor digitorum longus muscle. J Appl Physiol 73: 2538-2543.
126. Roy R, Dansereau G, Tremblay JP, Belles-Isles M, Huard J, Labrecque C and Bouchard JP (1991) Expression of major histocompatibility complex antigens on human myoblasts. Transplant Proc 23: 799-801.
127. Roy R, Tremblay JP, Huard J, Richards C, Malouin F and Bouchard JP (1993) Antibody formation after myoblast transplantation in Duchenne-dystrophic patients, donor HLA compatible. Transplant Proc 25: 995-997.
128. Satoh A, Labrecque C and Tremblay JP (1992) Myotubes can be formed within implanted adipose tissue. Transplant Proc 24: 3017-3019.
129. Schiaffino S, Bormioli SP and Aloisi M (1976) The fate of newly formed satellite cells during compensatory muscle hypertrophy. Virchows Arch B Cell Pathol 21: 113-118.
130. Schultz E, Jaryszak DL, Gibson MC and Albright DJ (1986) Absence of exogenous satellite cell contribution to regeneration of frozen skeletal muscle. J Muscle Res Cell Motil 7: 361-367.
131. Scale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P and Rudnicki MA (2000) Pax7 is required for the specification of myogenic satellite cells. Cell 102: 777-786.
132. Seigneurin-Venin S, Bernard V, Moisset PA, Ouellette MM, Mouly V, Di Donna S, Wright WE and Tremblay JP (2000a) Transplantation of normal and DMD myoblasts expressing the telomerase gene in SCID mice. Biochem Biophys Res Commun 272: 362-369.
133. Seigneurin-Venin S, Bernard V and Tremblay JP (2000b) Telomerase allows the immortalization of T antigen-positive DMD myoblasts: a new source of cells for gene transfer application. Gene Ther 1: 619-623.
134. 2+-dependent calcineurin signalling pathway. Nature 400: 576-581.
135. Sharp NJ, Kornegay JN, Bartlett RJ, Hung WY and Dykstra MJ (1993) Notexin-induced muscle injury in the dog. J Neurol Sci 116: 73-81.
136. Simon LV, Beauchamp JR, O'Hare M and Olsen I (1996) Establishment of long-term myogenic cultures from patients with Duchenne Muscular Dystrophy by retroviral transduction of a temperature-sensitive SV40 large T antigen. Exp Cell Res 224: 264-271.
137. Skuk D and Tremblay JP (1998) Complement deposition and cell death after myoblast transplantation. Cell Transplant 1: 427-434.
138. Skuk D and Tremblay JP (2001a) 'Engineering' myoblast transplantation. Graft 4: 558-570.
139. Skuk D and Tremblay JP (2001b) Myoblast transplantation. In: Atala A and Lanza R (eds) Methods of Tissue Engineering. Academic Press, San Diego.
140. Skuk D, Caron NJ, Goulet M, Roy B, Espinosa F and Tremblay JP (2002a) Dynamics of the early immune cellular reactions after myogenic-cell transplantation. Cell Transplant 11: 671-681.
141. Skuk D, Goulet M, Roy B and Tremblay JP (2000) Myoblast transplantation in whole muscle of nonhuman primates. J Neuropathol Exp Neurol 59: 197-206.
142. Skuk D, Goulet M, Roy B and Tremblay JP (2002b) Efficacy of myoblast transplantation in nonhuman primates following simple intramuscular cell injections: toward defining strategies applicable to humans. Exp Neurol 175: 112-126.
143. Skuk D, Roy B, Goulet M and Tremblay JP (1999) Successful myoblast transplantation in primates depends on appropriate cell delivery and induction of regeneration in the host muscle. Exp Neurol 155: 22-30.
144. Slierendregt BL, van Noort JT, Bakas RM, Otting N, Jonker M and Bontrop RE (1992) Evolutionary stability of transspecies major histocompatibility complex class II DRB lineages in humans and rhesus monkeys. Hum Immunol 35: 29-39.
145. Smythe GM, Fan Y and Grounds MD (2000) Enhanced migration and fusion of donor myoblasts in dystrophic and normal host muscle. Muscle Nerve 23: 560-574.
146. Tamaki T, Akatsuka A, Ando K, Nakamura Y, Matsuzawa H, Hotta T, Roy RR and Edgerton VR (2002) Identification of myogenicendothelial progenitor cells in the interstitial spaces of skeletal muscle. J Cell Biol 157: 571-577.
147. Thompson L (1992a) Cell-transplant results under fire. Science 257: 472-474.
148. Thompson L (1992b) Researchers call for time out on cell-transplant research. Science 257: 738.
149. Torrente Y, D'Angelo MG, Del Bo R, DeLiso A, Casati R, Benti R, Corti S, Comi GP, Gerundini P, Anichini A, Scarlato G and Bresolin N (1999) Extracorporeal circulation as a new experimental pathway for myoblast implantation in mdx mice. Cell Transplant 8: 247-258.
150. Torrente Y, El Fahime E, Caron NJ, Bresolin N and Tremblay JP (2000) Intramuscular migration of myoblasts transplanted after muscle pretreatment with metalloproteinases. Cell Transplant 9: 539-549.
151. Torrente Y, Tremblay J-P, Pisati F, Belicchi M, Rossi B, Sironi M, Fortunato F, El Fahime M, Grazia D'Angelo MG, Caron NJ, Constantin G, Paulin D, Scarlato G and Bresolin N (2001) Intraarterial Injection of Muscle-derived CD34 + Sca-1 + Stem Cells Restores Dystrophin in mdx Mice. J Cell Biol 152: 335-348.
152. Tremblay JP, Bouchard JP, Malouin F, Theau D, Cottrell F, Collin H, Rouche A, Gilgenkrantz S, Abbadi N, Tremblay M, et al. (1993a) Myoblast transplantation between monozygotic twin girl carriers of Duchenne muscular dystrophy. Neuromuscul Disord 3: 583-592.
153. Tremblay JP, Malouin F, Roy R, Huard J, Bouchard JP, Satoh A and Richards CL (1993b) Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 2: 99-112.
154. Vaidya TB, Rhodes SJ, Moore JL, Sherman DA, Konieczny SF and Taparowsky EJ (1992) Isolation and structural analysis of the rat MyoD gene. Gene 116: 223-230.
155. Vilquin JT, Asselin I, Guerette B, Kinoshita I, Lille S, Roy R and Tremblay JP (1994) Myoblast allotransplantation in mice: degree of success varies depending on the efficacy of various immunosuppressive treatments. Transplant Proc 26: 3372-3373.
156. Vilquin JT, Asselin I, Guerette B, Kinoshita I, Roy R and Tremblay JP (1995a) Successful myoblast allotransplantation in mdx mice using rapamycin. Transplantation 59: 422-426.
157. Vilquin JT, Guerette B, Puymirat J, Yaffe D, Tome FM, Fardeau M, Fiszman M, Schwartz K and Tremblay JP (1999) Myoblast transplantations lead to the expression of the laminin alpha 2 chain in normal and dystrophic (dy/dy) mouse muscles. Gene Ther 6: 792-800.
158. Vilquin JT, Kinoshita I, Roy B, Goulet M, Engvall E, Tome F, Fardeau M and Tremblay JP (1996) Partial laminin alpha2 chain restoration in alpha2 chain-deficient dy/dy mouse by primary muscle cell culture transplantation. J Cell Biol 133: 185-197.
159. Vilquin JT, Kinoshita I, Roy R and Tremblay JP (1995b) Cyclophosphamide immunosuppression does not permit successful myoblast allotransplantation in mouse. Neuromuscul Disord 5: 511-517.
160. Vilquin JT, Wagner E, Kinoshita I, Roy R and Tremblay JP (1995c) Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin. J Cell Biol 131: 975-988.
161. Wakeford S, Watt DJ and Partridge TA (1991) X-irradiation improves mdx mouse muscle as a model of myofiber loss in DMD. Muscle Nerve 14: 42-50.
162. Wakitani S, SaitoT and Caplan AI (1995) Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 18: 1417-1426.
163. Warrens AN, Zhang JY, Sidhu S, Watt DJ, Lombardi G, Sewry CA and Lechler RI (1994) Myoblasts fail to stimulate T cells but induce tolerance. Int Immunol 6: 847-853.
164. Watt DJ, Lambert K, Morgan JE, Partridge TA and Sloper JC (1982) Incorporation of donor muscle precursor cells into an area of muscle regeneration in the host mouse. J Neurol Sci 57: 319-331.
165. Webster C and Blau HM (1990) Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somat Cell Mol Genet 16: 557-565.
166. Weller B, Karpati G, Lehnert S, Carpenter S, Ajdukovic B and Holland P (1991) Inhibition of myosatellite cell proliferation by gamma irradiation does not prevent the age-related increase of the number of dystrophin-positive fibers in soleus muscles of mdx female heterozygote mice. Am J Pathol 138: 1497-1502.
167. Wernig A and Irintchev A (1995) 'Bystander' damage of host muscle caused by implantation of MHC-compatible myogenic cells. J Neurol Sci 130: 190-196.
168. Wernig A, Irintchev A and Lange G (1995) Functional effects of myoblast implantation into histoincompatible mice with or without immunosuppression. J Physiol (Lond) 484: 493-504.
169. Wernig A, Zweyer M and Irintchev A (2000) Function of skeletal muscle tissue formed after myoblast transplantation into irradiated mouse muscles. J Physiol (Lond) 522: 333-345.
170. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Weiss EH, Dichgans J, Lochmuller H, Hohlfeld R, Melms A and Weller M (2003) The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain 126: 176-185.
171. Yaffe D (1968) Retention of differentiation potentialities during prolonged cultivation of myogenic cells. Proc Natl Acad Sci USA 61: 477-483.
172. Yao SN and Kurachi K (1993) Implanted myoblasts not only fuse with myofibers but also survive as muscle precursor cells. J Cell Sci 105: 957-963.
173. Zammit PS, Heslop L, Hudon V, Rosenblatt JD, Tajbakhsh S, Buckingham ME, Beauchamp JR and Partridge TA (2002) Kinetics of myoblast proliferation show that resident satellite cells are competent to fully regenerate skeletal muscle fibers. Exp Cell Res 281: 39-49.
174. Zuk JA and Fletcher A (1988) Skeletal muscle expression of class II histocompatibility antigens (HLA-DR) in polymyositis and other muscle disorders with an inflammatory infiltrate. J Clin Pathol 41: 410-414.
175. Zvibel I, Smets F and Soriano H (2002) Anoikis: roadblock to cell transplantation? Cell Transplant 11: 621-630.